The Use of Hypomethylating Agents As A Therapeutic Against DNA Hypermethylation In ccRCC: A mock grant proposal for the National Institutes of Health written by Amirali Banani
Many research studies have demonstrated that DNA hypermethylation is linked to the development of clear cell renal cell carcinomas (ccRCC) by the transcriptional silencing of important tumor suppressor genes known as Von Hippel-Lindau (VHL). The results of these studies led me to ask the question, "could hypomethylating agents be used to demethylate the hypermethylated H3K4me1 marks of VHL tumor suppressor genes to reactivate the transcriptional activity of these genes?". This is the question that this entire proposal is based on. Following a guided approach that involves testing methods such as MeDIP, RT-qPCR, and Western Blotting to uncover the precise molecular mechanisms by which hypomethylating agents reactivate VHL genes, this mock NIH Grant Proposal essentially serves as a template for potential areas of research into this topic and approaches that can be taken to determine the efficacy of hypomethylating agents in suppressing the further development and progression of ccRCC. If successful, this epigenetic-based therapeutic technique could potentially be the first plausible cure for advanced stages of the malignancy.
1142956047
The Use of Hypomethylating Agents As A Therapeutic Against DNA Hypermethylation In ccRCC: A mock grant proposal for the National Institutes of Health written by Amirali Banani
Many research studies have demonstrated that DNA hypermethylation is linked to the development of clear cell renal cell carcinomas (ccRCC) by the transcriptional silencing of important tumor suppressor genes known as Von Hippel-Lindau (VHL). The results of these studies led me to ask the question, "could hypomethylating agents be used to demethylate the hypermethylated H3K4me1 marks of VHL tumor suppressor genes to reactivate the transcriptional activity of these genes?". This is the question that this entire proposal is based on. Following a guided approach that involves testing methods such as MeDIP, RT-qPCR, and Western Blotting to uncover the precise molecular mechanisms by which hypomethylating agents reactivate VHL genes, this mock NIH Grant Proposal essentially serves as a template for potential areas of research into this topic and approaches that can be taken to determine the efficacy of hypomethylating agents in suppressing the further development and progression of ccRCC. If successful, this epigenetic-based therapeutic technique could potentially be the first plausible cure for advanced stages of the malignancy.
0.0 In Stock
The Use of Hypomethylating Agents As A Therapeutic Against DNA Hypermethylation In ccRCC: A mock grant proposal for the National Institutes of Health written by Amirali Banani

The Use of Hypomethylating Agents As A Therapeutic Against DNA Hypermethylation In ccRCC: A mock grant proposal for the National Institutes of Health written by Amirali Banani

by Amirali Banani
The Use of Hypomethylating Agents As A Therapeutic Against DNA Hypermethylation In ccRCC: A mock grant proposal for the National Institutes of Health written by Amirali Banani

The Use of Hypomethylating Agents As A Therapeutic Against DNA Hypermethylation In ccRCC: A mock grant proposal for the National Institutes of Health written by Amirali Banani

by Amirali Banani

eBook

FREE

Available on Compatible NOOK devices, the free NOOK App and in My Digital Library.
WANT A NOOK?  Explore Now

Related collections and offers

LEND ME® See Details

Overview

Many research studies have demonstrated that DNA hypermethylation is linked to the development of clear cell renal cell carcinomas (ccRCC) by the transcriptional silencing of important tumor suppressor genes known as Von Hippel-Lindau (VHL). The results of these studies led me to ask the question, "could hypomethylating agents be used to demethylate the hypermethylated H3K4me1 marks of VHL tumor suppressor genes to reactivate the transcriptional activity of these genes?". This is the question that this entire proposal is based on. Following a guided approach that involves testing methods such as MeDIP, RT-qPCR, and Western Blotting to uncover the precise molecular mechanisms by which hypomethylating agents reactivate VHL genes, this mock NIH Grant Proposal essentially serves as a template for potential areas of research into this topic and approaches that can be taken to determine the efficacy of hypomethylating agents in suppressing the further development and progression of ccRCC. If successful, this epigenetic-based therapeutic technique could potentially be the first plausible cure for advanced stages of the malignancy.

Product Details

BN ID: 2940186615255
Publisher: Amirali Banani
Publication date: 01/17/2023
Sold by: Barnes & Noble
Format: eBook
Sales rank: 771,218
File size: 3 MB

About the Author

Amirali Banani is a passionate non-fiction writer from Vancouver, Canada who writes about a variety of fascinating topics in the ever changing world of science. Most of his books are about topics in the medical sciences and biology, two of which are based on articles he has written. Driven by curiosity and fascination for the natural world, Amirali is keen on understanding science on all scales. From the smallest molecules to the largest galaxies, he will take you into the depths of science in bite-size books rich in information.
From the B&N Reads Blog

Customer Reviews